pharmaphorum5d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...
Drug Store News24d
Axsome, Teva settle litigation over Auvelity
Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted, or on or after Sept. 30, 2038, if no pediatric ...
Hosted on MSN1mon
BofA raises Axsome stock target on extended Auvelity exclusivity
The adjustment comes after Axsome announced a patent settlement regarding its antidepressant drug, Auvelity. The settlement terms grant a license to Teva Pharmaceuticals, allowing them to ...
Nasdaq1mon
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
The litigation resulted from submission by Teva of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of AUVELITY in ...